Abstract
Congenital Cytomegalovirus infection is the leading non-genetic cause of neurosensory deafness. We compared the outcomes of a treated group of children to an untreated group. The effect of antiviral therapy on hearing improvement between baseline and 2-year follow-up was statistically significant. These results suggest that the benefit of 6-week therapy is not limited to preventing further hearing deterioration.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Cytomegalovirus Infections / congenital
-
Cytomegalovirus Infections / drug therapy*
-
Female
-
Ganciclovir / analogs & derivatives*
-
Ganciclovir / therapeutic use*
-
Hearing Loss, Sensorineural / congenital
-
Hearing Loss, Sensorineural / drug therapy*
-
Humans
-
Infant, Newborn
-
Male
-
Retrospective Studies
-
Valganciclovir
Substances
-
Antiviral Agents
-
Valganciclovir
-
Ganciclovir